The safety and efficacy of atezolizumab for recurrent primary liver cancer after liver transplantation

Abstract Background Immune checkpoint inhibitors (ICIs) have been proved to have certain therapeutic effects for primary liver cancer. However, the efficacy and safety of their applications in liver transplantation (LT) recipients with recurrent tumor remained unclear and even controversial. Methods...

Full description

Saved in:
Bibliographic Details
Main Authors: Rong-Rong Yao, Quan-Bao Zhang, Meng-Xi Ge, Li Li, Jing Li, Xin-Li Zhou, Zheng-Xin Wang, Xiao-Hua Liang
Format: Article
Language:English
Published: Springer 2025-04-01
Series:Discover Oncology
Subjects:
Online Access:https://doi.org/10.1007/s12672-025-02299-4
Tags: Add Tag
No Tags, Be the first to tag this record!